Tagged with Biotech,

China I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in January 2020, as well as shares some insights on the NASDAQ IPO experience.   Before the IPO, we might have…

Belgium Dirk Reyn of Flanders.bio highlights what the Flanders region has to offer the life sciences and biotech industries in terms of research infrastructure, funding opportunities, and inter-industry collaboration.   In the biotech/agro and foodtech area, Belgium and Flanders are in a very dynamic and positive period and we expect to…

South Korea South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion in its biopharma and biotech sectors over the next five years, the country’s prominence in the global biopharma landscape will…

China PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since we last met them in January 2019, including their March USD 75 million Series B+ fundraising round and their preparations…

Belgium Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes the country a perfect environment for Bone Therapeutics as a biotech company focusing on innovative cell and gene therapy.  …

Belgium PDC*Line Pharma’s Eric Halioua introduces the Belgian immuno-oncology biotech, its clinical-stage assets, the impact of the firm’s collaboration with Korean LG Chem, and future internationalisation strategies.   As a multicultural company, we believe in the future growth of Belgium’s innovative biotechnology sector. It is absolutely a country which should be…

Coronavirus Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from the novel coronavirus, COVID-19, now wreaking havoc around the world. But who exactly are the brains behind Clover Biopharmaceuticals and…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

Switzerland German biopharma giant Merck is investing EUR 250 million in a new Swiss biotech development facility; underscoring the company’s reliance on Switzerland for the manufacturing of advanced biologicals.   The Merck Biotech Development Center is to be located in Corsier-sur-Vevey, south-western Switzerland, close to the firm’s existing biotech commercial manufacturing…

Czech Republic Roman Badik, CEO of Enantis, the first biotechnology spin-off from Masaryk University in the Czech Republic, shares his vision of turning the company’s research breakthroughs into a self-sustaining business. Badik breaks down the business model of Enantis based on its proprietary protein stabilization platform and its lead compound FGF2-STAB with…

China Biosimilars are a relatively recent development in the pharmaceutical industry, meaning market penetration is still fairly low, even in many developed markets, much less emerging markets. Prior to 2019, not a single biosimilar had been approved in China. However, a McKinsey analysis found that biosimilars could account for a growing…

UK  A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing raised by UK biotechs in 2019 was down on the record year of 2018, but up on 2016 and 2017. Made with Visme Infographic Maker   A longer term perspective…